Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

BACKGROUND: The pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we evaluated treatment outcomes by degree of respiratory or cardiovascular dysfunction....

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Loeches, Ignacio, Shorr, Andrew F., Wunderink, Richard G., Kollef, Marin H., Timsit, Jean-François, Yu, Brian, Huntington, Jennifer A., Jensen, Erin, Bruno, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922343/
https://www.ncbi.nlm.nih.gov/pubmed/36773112
http://dx.doi.org/10.1186/s13613-022-01084-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922343/
https://www.ncbi.nlm.nih.gov/pubmed/36773112
http://dx.doi.org/10.1186/s13613-022-01084-8

Ejemplares similares